Research programme: peptides - APIM Therapeutics

Drug Profile

Research programme: peptides - APIM Therapeutics

Alternative Names: ATX 101

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator APIM Therapeutics; Norwegian university of science and technology
  • Class Peptides
  • Mechanism of Action Proliferating cell nuclear antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Bladder cancer; Breast cancer; Glioblastoma; Multiple myeloma; Prostate cancer

Most Recent Events

  • 07 Oct 2016 Preclinical trials in Bladder cancer in Norway (Intravesicular)
  • 07 Oct 2016 Preclinical trials in Glioblastoma in Norway (unspecified route)
  • 07 Oct 2016 APIM Therapeutics has patent protection for peptides comprising APIM-motif in USA, Japan, Australia and Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top